Current perspectives in the treatment of metastatic colorectal cancer

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Kohne C H ^a   Folprecht, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUDESONIDE; CAPECITABINE; CELECOXIB; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN; UFT;

ABDOMINAL CRAMP; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG EMBOLISM; METASTASIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT FAILURE; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 9744251552     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh904     Document Type: Article

References (95)

1. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903.
2. Piedbois P, Michelies S. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2,751 patients. Proc Am Soc Clin Oncol 2003; 22: 294 (Abstr 1180).
3. Van Cutsem E, Douillard JY, Köhne CH. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001; 345: 1351-1352.
4. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-464.
5. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
6. Borner MM, Schöffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
7. Hoff PM, Pazdur R, Benner SE, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9: 479-490.
8. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
9. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-1345.
10. Schilsky RL, Levin J, West WH et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002; 20: 1519-1526.
11. Van Cutsem E, Sorensen J, Cassidy J et al. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc, Am Soc Clin Oncol 2001; 20: 251a (Abstr 522).
12. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
13. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
14. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-3627.
15. Douillard JY, Hoff PM, Skillings JR et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-3616.
16. Salud A, Saigi E, Batiste-Alentorn E et al. Randomized phase IV trial of oral tegfur and low dose leucovorin versus intravenous 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer (ACC): Final results. Proc Am Soc Clin Oncol 2004; 23: 257 (Abstr 3547).
17. de Gramont A, Bosset JF, Milan C et al. A randomized trial comparing monthly low-dose leucovorin/fluorouracil bolus with bimonthly high-dose leucovorin/fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-815.
18. Weh HJ, Zschaber R, Braumann D et al. A randomized phase III study comparing weekly folinic acid (FA) and high dose 5-Fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carinoma. Onkologie 1998; 21: 403-407.
19. Köhne CH, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-3728.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine, therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
22. Bertolini A, Flumano M, Fusco O et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001; 87: 200-206.
23. Hoff PM, Pazdur R, Lassere Y et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004; 22: 2078-2083.
24. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
25. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
26. Ulrich-Pur H, Kornek GV, Fiebiger W et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12: 1269-1272.
27. Fuchs CS, Moore MR, Harker G et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807-814.
28. Andre T, Louvet C, Maindrault-Goebel F et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-1347.
29. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
30. Köhne CH, Van Cutsem E, Wils J et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003; 22: 254 (Abstr 1018).
31. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
32. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
33. Rothenberg M, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
34. Kakkar AK, Williamson RC. Antithrombotic therapy in cancer. BMJ 1999; 318: 1571-1572.
35. Levine MN, Gent M, Hirsh J et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407.
36. Rothenberg ML, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
37. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28: 482-483.
38. Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10: 1251-1253.
39. Merrouche Y, Extra JM, Abigerges D et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol 1997; 15: 1080-1086.
40. Ychou M, Raoul JL, Desseigne F et al. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 2002; 50: 383-391.
41. Ducreux M, Kohne CH, Schwartz GK, Vanhoefer U. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Ann Oncol 2003; 14 (Suppl 2): ii17-ii23.
42. Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric trial. Ann Oncol 1998; 9: 105-108.
43. Machover D, Diaz Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-98.
44. Raymond E, Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876-885.
45. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
46. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
47. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
48. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 156.
49. Kohne CH, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-3728.
50. de Gramont A, Cervantes A, Andre T et al. OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 251.
51. Rougier P, Lepille D, Bennouna J et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002; 13: 1558-1567.
52. Becouarn Y, Gamelin E, Coudert B et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 4195-4201.
53. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
54. Heinemann V, Schalhorn A, Fischer von Weikersthal L et al. Phase III trial: Irinotecan plus oxaliplatin versus irinotecan plus 5-fluorouracil/folinic acid (FA) for first line treatment of metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004; 22: 274.
55. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
56. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-1766.
57. Tewes M, Schleucher N, Achterrath W et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol 2003; 14: 1442-1448.
58. Kerr DJ, ten Bokkel Huinink WW, Ferry D et al. A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 643.
59. Jordan K, Grothey A, Kellner O et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): results of an interim analysis. Proc Am Soc Clin Oncol 2002; 21: 2225.
60. Arkenau HT, Schmoll HJ, Kubicka S et al. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal cancer (ACRC): Results of an interim safety analysis. Proc Am Soc Clin Oncol 2004; 23: 257.
61. Gil-Delgado MA, Bastian G, Guinet F et al. Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinefic analysis in advanced colorectal cancer patients. Am J Clin Oncol 2004; 27: 294-298.
62. Ychou M, Conroy T, Seitz JF et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003; 14: 481-489.
63. Souglakos J, Mavroudis D, Kakolyris S et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002; 20: 2651-2657.
64. Goetz MP, Erlichman C, Windebank AJ et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21: 3761-3769.
65. Calvo E, Cortes J, Rodriguez J et al. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002; 2: 104-110.
66. Souglakos J, Ziras N, Polyzos A et al. Oxaliplatin (l-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first line treatment for metastatic colorectal cancer (MCC): preliminary results of a multicenter randomised phase III trial. Proc Am Soc Clin Oncol 2004; 23: 253.
67. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
68. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
69. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
70. Knight RD, Miller LL, Pirotta N et al. First line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol 2000; 19: 991.
71. Köhne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
72. Tournigand C, Andre T, Chirivella I et al. 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in poor prognosis patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 261.
73. Wein A, Riedel C, Kockerling F et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001; 12: 1721-1727.
74. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
75. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520.
76. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353.
77. Alberts SR, Donohue JH, Mahoney MR et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 2003; 22: 263.
78. Ychou M, Nordlinger B, Quenet F et al. CPT-11/L-OHP/5-FU/LV combination before liver surgery in patients with not optimally resectable colorectal cancer liver metastases: methodology and preliminary results, phase II study. Proc Am Soc Clin Oncol 2002; 21: 162a.
79. Roth AD, Seium Y, Ruhstaller T et al. Oxaliplatin (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): a phase I-II study. Proc Am Soc Clin Oncol 2002; 21: 143a.
80. Elias D, Youssef O, Sideris L et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Sing Oncol 2004; 86: 4-9.
81. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003; 22: 254.
82. Cunningham D, Humblet Y, Siena D et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 256.
83. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
84. Fuchs CS, Moore MR, Harker G et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807-814.
85. Cassata A, Stani SC, Alu M et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001; 20: 573.
86. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
87. Borner M, Dietrich D, Popescu R et al. A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 2003; 22: 178.
88. Shields AF, Zalupski MM, Marschall JL, Meropol NJ. A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21: 568.
89. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-1312.
90. Escudero P, Alonso V, Puertolas T et al. Weekly irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma (ACRC). Proc Am Soc Clin Oncol 2002; 21: 2238.
91. Cruz JJ, Méndez M, Pujol E et al. Weekly irinotecan (CPT-11) in combination with oral uracil and ftorafur (UFT) plus folinic acid (FA) as first line treatment in advanced colorectal cancer (CRC). Preliminary results. Proc Am Soc Clin Oncol 2001; 20: 2186.
92. Douillard J-Y, Bennouna J, Artru AA et al. UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients (Pts) with non resectable metastatic colorectal cancer (MCRC): results of two multicenter phase II trials. Proc Am Soc Clin Oncol 2004; 23: 256.
93. Garcia-Girón C, Feliu J, Vincent JM et al. Phase II trial of oxaliplatin-UFT-leucovorin (OXA-UFT-LV) combination in first line treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2000; 19: 1148.
94. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
95. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.